Compare Ginkgo Bioworks Holdings Inc (DNA) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13.32 (market cap $763.64M), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 11.1× Ginkgo Bioworks Holdings Inc's market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | QYLD | |
|---|---|---|
Market Cap | $763.64M | $8.49B |
Volume | 3,204,177 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $15.83 | $18.68 |
52-Week Low | $5.48 | $16.70 |
Typical Hold Time | 7 Days | — |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
QYLD trades at $18.675, down slightly by 0.03% on the day. The ETF shows a bullish technical signal from moving averages but bearish oscillators, with RSI levels indicating potential overbought conditions. Recent dividend payments of $0.18 per share were distributed monthly, supporting its income-focused strategy. News coverage highlights its high yield but also raises concerns about long-term capital erosion and capped upside.
The outlook for QYLD is mixed; it offers attractive monthly income but faces headwinds from declining option premiums and limited growth potential. Risks include principal erosion and tax implications, making it suitable for income-seeking investors who prioritize cash flow over capital appreciation. Analyst sentiment varies, with some upgrades citing yield attractiveness amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
